

# CURRICULUM VITAE

## Dott. Alberto Floris

**CURRENT POSITION** Tenure-Track Researcher (RTT) at the Department of Medical Sciences and Public Health, University of Cagliari, and the Rheumatology Unit (UOC) at the University Hospital of Cagliari.

**REGISTRATIONS** Order of Physicians and Dentists of Cagliari No. 9205 since August 11, 2009.

Member of the Italian Society of Rheumatology (SIR) since 2012

**BIBLIOMETRIC INDICES**  
(al 24-04-2025)

Data source: Scopus

N documents	N citaations	H index
59	1086*	19*

**ACADEMIC AND PROFESSIONAL QUALIFICATIONS**

Italian National Scientific Qualification for Associate Professor (Second Level) in the Academic Recruitment Field 06/D3 – Blood Diseases, Oncology, and Rheumatology (date 09-06-2023)

Second-level Master's Degree in "Translational Research in Rheumatology" (Academic Year 2015/2016), awarded by the University of Trieste, with a grade of 110/110 (date 11/12/2017)

Specialization achievement in Rheumatology, awarded by the University of Cagliari with a grade of 50/50 cum laude (date 05/06/2015)

Medical licensure obtained at the University of Cagliari (1st session 2009), with registration in the Provincial Board of Physicians and Dentists of Cagliari under No. 9205 (date 11/08/2009)Laurea

Degree in Medicine and Surgery, awarded by the University of Cagliari with a grade of 110/110 cum laude (date 17/12/2008)

**RESEARCH AND TRAINING ACTIVITIES**

**31/12/2024 - today** Research and clinical activity as a Tenure-Track Researcher (RTT) at the Department of Medical Sciences and Public Health, University of Cagliari, and at the Rheumatology Unit (UOC) of the University Hospital (AOU) of Cagliari.

**31/12/2021 - 30/12/2024** Research and clinical activity as a Researcher type A (RTD-A) at the Department of Medical Sciences and Public Health, University of Cagliari, and at the Rheumatology Unit (UOC) of the AOU of Cagliari, following a competitive selection for positions funded by the PON "Research and Innovation" program.

**04/05/2018 - 10/11/2021** Research Fellow at the Rheumatology Unit of the Department of Medical Sciences and Public Health, University of Cagliari, with integrated clinical activity at the UOC of Rheumatology at the AOU of Cagliari.

**02/05/2017 - 1/05/2018** Research activity at the Rheumatology Unit of the University and AOU of Cagliari, following a successful application for a scholarship awarded by the Italian Society of Rheumatology.

15/01/20 - 11/12/17	Second-level Master's Degree in "Translational Research in Rheumatology" (Academic Year 2015/2016), obtained at the University of Trieste with a grade of 110/110.
16/04/16 - 15/04/17	Clinical and research activity at the Rheumatology Unit of the AOU of Cagliari, after winning a public competitive selection for a full-time freelance contract as a Specialist in Rheumatology.
15/03/15 - 18/02/16	Research activity at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford (UK), following successful selection for a scholarship awarded by the Italian Society of Rheumatology for the project: "Diagnostic and Classification Criteria for Vasculitis and Ultrasound Assessment of Giant Cell Arteritis."
04/05/10 - 5/06/15	Clinical-assistance and research activity carried out during the training program of the Rheumatology Specialization School (Academic Year of enrollment 2009/2010; course duration 5 years) at the University of Cagliari, concluded on 05/06/2015, with the attainment of the specialization diploma with a grade of 50/50 with honors.

## PROJECT ACTIVITIES

Member of the Executive Committee and co-responsible for the conception, design, and methodological construction, as well as coordinator for the implementation of the prospective study project DIAPASON (Early Diagnosis of Psoriatic Arthritis In A Monocentric Cohort Of Patients With Psoriasis) doi.org/10.3390/jcm12186090; doi.org/10.1093/rheumatology/keae257.

Member of the Executive Committee and co-responsible for the conception, design, methodological development, and coordination of the international multicenter project PROspective multiethnic validation of the BEhçet's syndrome Overall Damage Index (BODI): the PROBE study.

Study Site Coordinator (with responsibilities in design, methodological development, and implementation) of the project "Assessment of the anti-CarP, anti-R33 and anti-PAD4 autoantibodies as predictors of response to abatacept in a real-life cohort of rheumatoid arthritis patients", funded by Bristol-Myers Squibb International Corporation (BMS) following an international selection and review process by a Request for Proposal (RFP) Committee composed of experts in the therapeutic area of interest (Immunoscience).

Principal investigator of the study "Endothelial biomarkers for Behçet Disease (EMBED) – Assessment of Circulating Endothelial Cells, Progenitor Endothelial Cells, and Endothelial Microparticles as Biomarkers in Behçet's disease", funded by the Italian Association for Behçet's Disease and Syndrome (S.I.M.B.A.) through a competitive grant call. Sponsor: SIMBA Onlus.

Proposer, scientific lead, and coordinator of the international multicenter project "Assessment of the impact of organ damage on the quality of life in patients with Behçet's Syndrome: a prospective study in an international multicenter cohort", funded by the Italian Association for Behçet's Disease and Syndrome (S.I.M.B.A.) through a competitive grant call. Funding body: SIMBA Onlus.

Member of the Steering Committee and co-responsible for the conception, design, and methodological construction of the International Multicenter BODI Study (Behçet's Overall syndrome Damage Index), funded by the Italian Association for Behçet's Disease and Syndrome (S.I.M.B.A.) through a competitive grant call. Sponsor: SIMBA Onlus.

Contributor as co-responsible for methodological design, data collection, analysis, and final interpretation in the project "Profiling of Rheumatoid Arthritis patients with Inadequate response (PRAISE) to conventional and biological DMARDs. Focus on the potential predictive value of functional BAFF polymorphisms." The project received funding through a competitive selection as part of the National CREARE Program - Pfizer.

Participation in the research activities of the study "The BAFF-var polymorphism as a biomarker of response to B-depleting treatment in patients affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis (PREDICT)": a prospective single-center cohort study funded by the University of Cagliari.

## AWARDS AND RECOGNITIONS

- 23/11/17** | Winner of the award for Best Oral Presentation in English in the “Towards EULAR 2020” Session at the 54th Italian Society of Rheumatology Conference (Rimini, November 22–24, 2017), with the scientific contribution titled “Lupus Low Disease Activity State (LLDAS) in Caucasian patients: prevalence and outcome in the first 18 months of systemic lupus erythematosus.”
- 22/11/17** | Recipient of a one-year research grant awarded by the Italian Society of Rheumatology, following a competitive selection, for the project: “Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in Behçet’s disease: evaluation of their possible pathogenic significance and potential role as biomarkers.”
- 26/11/14** | Recipient of a 9-month research grant awarded by the Italian Society of Rheumatology, following a competitive selection, for the project: “Diagnostic and Classification Criteria for Vasculitis and Ultrasound Assessment of Giant Cell Arteritis.”
- 24/11/2012** | Winner of the Best Poster Award in the “Vasculitis” Session at the 49th National Congress of the Italian Society of Rheumatology (2012), for the abstract titled “Small vessel vasculitis during bacterial endocarditis.” Congress Proceedings, P64, page 372.

**PUBBLICAZIONI SCIENTIFICHE IN  
ESTENSO**

1. Floris A, Mugheddu C, Sichi L, Anedda J, Frau A, Sorgia J, Li volsi L, Paladino MT, Congia M, Chessa E, Angioni MM, Naitza M, Ferrelli C, Piga M, Atzori L, Cauli A. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. *Rheumatology (Oxford)* 2024 May 23:keae257. doi: 10.1093/rheumatology/keae257.
2. Chessa E, Floris A, Congia M, Angioni MM, Piga M, Gossec L, Cauli A. Psychometric Properties of Patient Global Assessment in Psoriatic Arthritis: A Systematic Literature Review. *J Rheumatol* 2024 Jun 1;51(6):603-612. doi: 10.3899/jrheum.2023-0722.
3. Primavera D, Carta MF, Romano F, Sancassini F, Chessa E, Floris A, Cossu G, Nardi EA, Piga M, Cauli A. Quality of Life in Systemic Lupus Erythematosus and Other Chronic Diseases: Highlighting the Amplified Impact of Depressive Episodes Healthcare (Basel) 2024 Jan 17;12(2):233. doi: 10.3390/healthcare12020233
4. Floris A, Laconi R, Espinosa R, Lopalco G, Serpa Pinto L, Kougkas N, Sota J, Lo Monaco A, Govoni M, Fabiani C, Bertias G, Correia J, Iannone F, Cervera R, Vasconcelos C, Mathieu A, Cauli A, Piga M. Organ damage is a major determinant of work productivity impairment in Behçet's Syndrome: a post-hoc analysis of the BODI validation study. *Rheumatology (Oxford)* 2023 Dec 13:kead681. doi: 10.1093/rheumatology/kead681
5. Angioni MM, Floris A, Cangemi I, Congia M, Chessa E, Naitza M, Piga M, Cauli A. Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study. *Front Immunol* 2023 Oct 27;14:1274539. doi: 10.3389/fimmu.2023.1274539. eCollection 2023.
6. Chessa E, Piga M, Perra A, Pintus E, Porcu M, Serafini C, Congia M, Angioni MM, Naitza MR, Floris A, Mathieu A, Saba L, Carta MG, Cauli A. Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study. *Lupus Sci Med* 2023 Nov;10(2):e001005. doi: 10.1136/lupus-2023-001005.
7. Floris A, Mugheddu C, Sichi L, Dessi M, Anedda J, Frau A, Pau A, Lari SA, Sorgia J, Li Volsi L, Paladino MT, Congia M, Chessa E, Angioni MM, Ferrelli C, Piga M, Atzori L, Cauli A. The Challenging Differentiation of Psoriatic Arthritis from Other Arthropathies and Nonspecific Arthralgias in Patients with Psoriasis: Results of a Cross-Sectional Rheumatologic Assessment of a Large Dermatologic Cohort. *J Clin Med*. 2023 Sep 21;12(18):6090. doi: 10.3390/jcm12186090.
8. Cocco C, Manca E, Corda G, Angioni MM, Noli B, Congia M, Loy F, Isola M, Chessa E, Floris A, Lorefice L, Saba L, Mathieu A, Ferri GL, Cauli A, Piga M. Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus. *Front Immunol*. 2023 Jun 13;14:1157149. doi: 10.3389/fimmu.2023.1157149. eCollection 2023.
9. Sanna GD, Piga M, Piga A, Falco O, Ponti E, Cauli A, Floris A, Mangoni AA, Casu G, De Luca G, Erre GL; EDRA Study Group. Prevalence and clinical significance of electrocardiographic signs of atrial myopathy in rheumatoid arthritis: results from the EDRA study. *Clin Exp Rheumatol*. 2023 Jul;41(7):1427-1433. doi: 10.55563/clinexprheumatol/d9l4lt.

10. Floris A, Chessa E, Sebastiani GD, Prevete I, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Franceschini F, Fredi M, Conti F, Romana Spinelli F, Bellisai F, D'Alessandro Roberto, Zanetti A, Carrara G, Scirà CA, Alberto C, Piga M. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study. *RMD Open* 2022 Dec;8(2):e002701. doi: 10.1136/rmdopen-2022-002701
11. Floris A, Piga M, Laconi R, Espinosa G, Lopalco G, Serpa Pinto L, Kougkas N, Sota J, Lo Monaco A, Govoni M, Cantarini L, Bertsias G, Correia J, Iannone F, Cervera R, Vasconcelos C, Mathieu A, Cauli A. Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study. *Arthritis Res Ther.* 2022 Nov 17;24(1):253. doi: 10.1186/s13075-022-02947-y.
12. Parisi S, Zanetti A, Carrara G, Scirà CA, Iagnocco A, Filippou G; STARTER Investigators (Floris A among the STARTER investigators). Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study. *Rheumatology (Oxford).* 2023 Apr 3;62(4):1485-1492. doi: 10.1093/rheumatology/keac518.
13. Floris A, Rozza D, Zanetti A, Carrara G, Bellis E, Cauli A, Iagnocco A, Scirà CA, Piga M. Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity. *RHEUMATOLOGY*, vol. 62, p. 116-123, ISSN: 1462-0332, doi: 10.1093/rheumatology/keac255
14. Cacciapaglia F, Spinelli FR, Piga M, Erre GL, Sakellariou G, Manfredi A, Viapiana O, Fornaro M, Colella S, Floris A, Mangoni AA, Castagna F, Vacchi C, Orsolini G, Bugatti S, Cafaro G, Cauli A, Gremese E, Atzeni F, Bartoloni E. Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group. *EUROPEAN JOURNAL OF INTERNAL MEDICINE*, vol. 96, p. 60-65, ISSN: 0953-6205, doi: 10.1016/j.ejim.2021.10.001
15. Gaggiano C, Rigante D, Hernández-Rodríguez J, Vitale A, Tarsia M, Soriano A, Lopalco G, Iannone F, Abdel Jaber M, Giacomelli R, Więsik-Szewczyk E, Cattalini M, Frassi M, Piga M, Ragab G, Sota J, Zunica F, Floris A, Sabato V, Hegazy MT, Araújo O, Pelegrin L, Fabbiani A, Renieri A, Grosso S, Fabiani C, Frediani B, Cantarini L. Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. *Ther Adv Musculoskelet Dis.* 2021 Sep 9;13:1759720X211037178. doi: 10.1177/1759720X211037178.
16. Floris A, Piga M, Chessa E, Congia M, Erre GL, Angioni MM, Mathieu A, Cauli A (2022). Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. *CLINICAL RHEUMATOLOGY*, vol. 41, p. 19-31, ISSN: 1434-9949, doi: 10.1007/s10067-021-05819-z
17. Piga, Matteo, Floris, Alberto, Congia, Mattia, Chessa, Elisabetta, Cangemi, Ignazio, Cauli, Alberto (2022). Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. *RHEUMATOLOGY*, vol. 61, p. 1795-1801, ISSN: 1462-0324, doi: 10.1093/rheumatology/keab632.
18. Mangoni AA, Woodman RJ, Piga M, Cauli A, Fedele AL, Gremese E, Erre GL; EDRA Study Group (including Floris A). Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis. *Front Cardiovasc Med.* 2021 Jul 19;8:681327. doi: 10.3389/fcvm.2021.681327. eCollection 2021.
19. Floris A., Congia M., Chessa E., Angioni M. M., Piga M., Cauli A. (2021). Targeted Therapies in Axial Psoriatic Arthritis. *FRONTIERS IN GENETICS*, vol. 12, p. 1-7, ISSN: 1664-8021, doi: 10.3389/fgene.2021.689984
20. Floris A, Perra D, Cangemi I, Congia M, Chessa E, Angioni MM, Mangoni AA, Erre GL, Mathieu A, Piga M, Cauli A. Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs: Results from a retrospective cohort study. *Medicine (Baltimore).* 2021 Apr 30;100(17):e25481.
21. Bettiol A, Sinico RA, Schiavon F, Monti S, Bozzolo EP, Franceschini F, Govoni M, Lunardi C, Guida G, Lopalco G, Paolazzi G, Vacca A, et al and EGPA Consortium (including Floris A). Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). *Eur Respir J.* 2021 May 6;57(5):2004158. doi: 10.1183/13993003.04158-2020

22. Angioni M. M., Floris A., Cangemi I., Congia M., Chessa E., Orru S., Piga M., Cauli A. (2021). Gene expression profiling of monozygotic twins affected by psoriatic arthritis. *OPEN ACCESS RHEUMATOLOGY*, vol. 13, p. 23-29, ISSN: 1179-156X, doi: 10.2147/OARRR.S291391
23. Chessa E, Piga M, Floris A, Congia M, Cangemi I, Mathieu A, Cauli A. Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. *BioDrugs*. 2021 Mar;35(2):175-186. doi: 10.1007/s40259-021-00467-w. Epub 2021 Feb 17
24. Piga M, Congia M, Balestrieri A, Angioni MM, Cangemi I, Cau R, Chessa E, Floris A, Figus F, Iagnocco A, Cauli A, Saba L. Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud's arthropathy and a distinctive MRI pattern. *Rheumatology (Oxford)*. 2021 Sep 1;60(9):4218-4228. doi: 10.1093/rheumatology/keaa915.
25. Floris A, Espinosa G, Serpa Pinto L, Kougkas N, Lo Monaco A, Lopalco G, Orlando I, Bertias G, Cantarini L, Cervera R, Correia J, Govoni M, Iannone F, Mathieu A, Neri P, Martins Silva A, Vasconcelos C, Muntoni M, Cauli A, Piga M; BODI Project collaborators. Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. *Arthritis Res Ther*. 2020 Nov 25;22(1):278. doi: 10.1186/s13075-020-02362-1.
26. Bassu S, Zinellu A, Sotgia S, Mangoni AA, Floris A, Farina G, Passiu G, Carru C, Erre GL. Oxidative Stress Biomarkers and Peripheral Endothelial Dysfunction in Rheumatoid Arthritis: A Monocentric Cross-Sectional Case-Control Study. *Molecules* 2020;25(17):3855. doi: 10.3390/molecules25173855
27. Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L. Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. *Rheumatology (Oxford)* 2020 Aug 13;keaa383. doi: 10.1093/rheumatology/keaa383.
28. Erre GL, Sebastiani M, Fenu MA, Zinellu A, Floris A, Cavagna L, Renzoni E, Manfredi A, Passiu G, Woodman RJ, Mangoni AA. Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. *J Clin Med* 2020;9(8): 2560 doi: 10.3390/jcm9082560
29. Piga M, Floris A, Espinosa G, Serpa Pinto L, Kougkas N, Lo Monaco A, Lopalco G, Orlando I, Pirani V, Santos E, Bertias G, Cantarini L, Cauli A, Cervera R, Correia J, Govoni M, Iannone F, Neri P, Martins Silva A, Vasconcelos C, Muntoni M, Mathieu A, and the BODI Project Group. Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI). *RMD open* 2020;6(2):e001192. doi: 10.1136/rmdopen-2020-001192.
30. Piga M, Floris A, Sebastiani GD, Prevete I, Iannone F, Coladonato L, Govoni M, Bortoluzzi A, Mosca M, Tani C, Doria A, Iaccarino L, Franceschini F, Fredi M, Conti F, Spinelli FR, Galeazzi M, Bellisai F, Zanetti A, Carrara G, Scirè CA, Mathieu A. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. *Rheumatology (Oxford)*. 2019 Dec 16. pii: kez584. doi: 10.1093/rheumatology/kez584
31. Floris A, Piga M, Pinna S, Angioni MM, Congia M, Mascia P, Chessa E, Cangemi I, Mathieu A, Cauli A. Assessment Of Circulating Endothelial Cells And Their Progenitors As Potential Biomarkers Of Disease Activity And Damage Accrual In Behçet's Syndrome. *Open Access Rheumatol*. 2019 Oct 8;11:219-227. doi: 10.2147/OARRR.S225168.
32. Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, Cauli A. Treatment target in newly diagnosed Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)*. 2019 Oct 10. doi: 10.1002/acr.24086.
33. Angioni MM, Piga M, Paladini F, Lai S, Erre GL, Floris A, Cauli A, Fiorillo MT, Passiu G, Carcassi C, Sorrentino R, Mathieu A. AIF-1 gene does not confer susceptibility to Behçet's disease: Analysis of extended haplotypes in Sardinian population. *PLoS One*. 2018 Sep 25;13(9):e0204250.
34. Cauli A, Dessole G, Piga M, Angioni MM, Pinna S, Floris A, Congia M, Mascia E, Paladini F, Tedeschi V, Sorrentino R, Fiorillo MT, Mathieu A. Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis. *RMD Open*. 2018 Jul 13;4(2):e000597.
35. Floris A, Piga M, Cauli A, Salvarani C, Mathieu A. Polymyalgia rheumatica: an autoinflammatory disorder? *RMD Open*. 2018 Jun 4;4(1):e000694.

36. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kujik AWR, Catanoso MG, Caso F, Contu P, Ujjalussy I, Helliwell PS, Mease PJ; GRAPPA 3PPSA Study Group. Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. *J Rheumatol.* 2018 Aug;45(9):1256-1262.
37. Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. *Mediators of Inflammation* 2018 Jan 18; Volume 2018, article ID: 3424136. doi: 10.1155/2018/3424136.
38. Chessa E, Piga M, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. *Reumatismo.* 2017 Dec 21;69(4):175-183. doi: 10.4081/reumatismo.2017.1007.
39. Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A, Cauli A. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. *Arthritis Research & Therapy.* 2017 Nov 10;19:247. doi: 10.1186/s13075-017-1451-5.
40. Monti S, Floris A, Ponte CB, Schmidt WA, Diamantopoulos AP, Pereira C, Vaggers S, Luqmani RA. The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. *Rheumatology (Oxford)* 2018 Jan 1;57(1):112-119. doi: 10.1093/rheumatology/kex341.
41. Chessa E, Piga M, Floris A, Mathieu A, Cauli A. Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care. *Open Access Rheumatology: Research and Reviews* 2017 Sep 11;9:167-170. doi: 10.2147/OARRR.S143768. eCollection 2017.
42. Piga M, Floris A, Mathieu A, Cauli A. Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. *Rheumatology (Oxford)* 2017 Nov 1;56(11):2038-2039. doi: 10.1093/rheumatology/kex313.
43. Piga M, Congia M, Gabba A, Figus F, Floris A, Mathieu A, Cauli A. Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus. *Lupus* 2018 Feb;27(2):190-198. doi: 10.1177/0961203317716319.
44. Monti S, Floris A, Ponte C, Schmidt WA, Diamantopoulos AP, Pereira C, Piper J, Luqmani R. The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. *Rheumatology (Oxford).* 2018 Feb 1;57(2):227-235. doi: 10.1093/rheumatology/kex173.
45. Piga M, Chessa E, Peltz MT, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. *Autoimmunity Review* 2017 Mar;16(3):244-252. doi: 10.1016/j.autrev.2017.01.011.
46. Piga M, Pesella F, Corrairie ML, Floris A, Cauli A, Mathieu A. PET/CT scan revealing active idiopathic inflammatory myopathy with normal serum sarcoplasmic enzymes levels. *Clinical Experimental Rheumatology.* 2016 Jul-Aug;34(4):723-4.
47. Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. *Autoimmunity Review* 2016 Jul;15(7):656-63. doi: 10.1016/j.autrev.2016.02.019.
48. Cauli A, Piga M, Lubrano E, Marchesoni A, Floris A, Mathieu A. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol. *The Journal of Rheumatology* 2015, 93:70-72, doi: 10.3899/jrheum.150641.
49. Piga M, Casula L, Sanna S, Perra D, Floris A, Antonelli A, Cauli A, Mathieu A. Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001–2012. *Rheumatology International* 2016 Jan;36(1):73-81, doi: 10.1007/s00296-015-3330-1.

50. Piga M, Casula L, Perra D, Sanna S, Floris A, Antonelli A, Cauli A, Mathieu A. Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. *Lupus* 2016 Jan;25(1):28-37, doi: 10.1177/0961203315596597.
51. Cauli A, Piga M, Floris A, Mathieu A. Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis). *Journal of ImmunoTargets and Therapy* 2015 Oct 1;4:185-190 doi: <http://dx.doi.org/10.2147/ITT.S62870>.
52. Cauli A, Piga M, Dessole G, Porru G, Floris A, Vacca A, Desogus E, La Nasa G, Mathieu A. Killer-Cell Immunoglobulin-Like Receptor (KIR) and HLA-Class I Heavy Chains in Ankylosing Spondylitis. *Drug Development Research* 2014 Nov;75 Suppl 1:S15-9. doi: 10.1002/ddr.21187.
53. Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, Mathieu A. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. *Autoimmunity Reviews*. 2014 Aug;13(8):873-9. doi: 10.1016/j.autrev.2014.05.005

#### LANGUAGE SKILLS

<b>Mother tongue</b>	Italian
<b>Other Languages</b>	English (CEFR Level: B2)

Luogo e data\_CAGLIARI 24-04-2025

Dr Alberto Floris